- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Session 2: Discussant
Wade M. Aubry, MD, associate clinical professor, University of California, San Francisco, continues discussions saying that comparative effectiveness research (CER) and the evolution of evidence-based medicine can facilitate innovations under the Affordable Care Act (ACA), especially with the inclusion of value-based insurance design (VBID).
Wade M. Aubry, MD, associate clinical professor, University of California, San Francisco, continues discussions saying that comparative effectiveness research (CER) and the evolution of evidence-based medicine can facilitate innovations under the Affordable Care Act (ACA), especially with the inclusion of value-based insurance design (VBID).
Dr Aubrey notes that the ACA’s aim is to address problems in the US healthcare system that leads to high costs and low-quality healthcare delivery. Several initiatives in the ACA, like CER established by the Patient-Centered Clinical Research Network Initiative (PICORI), promote evidence-based medicine which furthers the evolution of systems like pay-for-performance initiatives, and the establishment of accountable care organizations.
Under CER, specifically in managing diabetes, there is a need for better evidence regarding alternative interventions including diagnostic, therapeutic, and other systems or strategies. VBID in diabetes has the potential to incentivize high- value services, and de-incentivize low-value services. As well, ACA recommendations made by the US Preventive Services Task Force pushes screening for diabetes as a high-value preventive services that must be included in VBID health plans.
“I think the future of CER is good and that it will increasingly be applied to these types of value-based insurance designs, formularies, or medical policies with differentials copays to promote high-value care and discourage low value care,” Dr Aubry said.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
